Neurofilament light chain in the assessment of patients with multiple sclerosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos de neuro-psiquiatria (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000600436 |
Resumo: | ABSTRACT Multiple sclerosis (MS) is an autoimmune, inflammatory, and degenerative disease of the central nervous system. Axonal degeneration is triggered by inflammation and is the pathological substrate of progressive disability in patients with MS. Therapeutic interventions can reduce inflammatory activity, thus delaying neurodegeneration and the progression of disability. Disease activity and neurodegeneration are assessed mainly through clinical evaluation and magnetic resonance imaging. These measures lack sensitivity and accuracy, so new biomarkers are necessary. Several markers have been studied and to date the most promising is neurofilament light (NfL), a component of the axonal cytoskeleton, which is released into cerebrospinal fluid (CSF) following axonal damage. In the present study, we review the current knowledge about CSF NfL determination in MS, clinically isolated syndrome, and radiologically isolated syndrome, and critically discuss how CSF NfL measurement may contribute to therapeutic decision-making in these patients. |
id |
ABNEURO-1_1ec60fd2353865602cf35e057f4be611 |
---|---|
oai_identifier_str |
oai:scielo:S0004-282X2019000600436 |
network_acronym_str |
ABNEURO-1 |
network_name_str |
Arquivos de neuro-psiquiatria (Online) |
repository_id_str |
|
spelling |
Neurofilament light chain in the assessment of patients with multiple sclerosisMultiple sclerosiscerebrospinal fluidneurofilament proteinsdemyelinating disordersenzyme-linked immunosorbent assayABSTRACT Multiple sclerosis (MS) is an autoimmune, inflammatory, and degenerative disease of the central nervous system. Axonal degeneration is triggered by inflammation and is the pathological substrate of progressive disability in patients with MS. Therapeutic interventions can reduce inflammatory activity, thus delaying neurodegeneration and the progression of disability. Disease activity and neurodegeneration are assessed mainly through clinical evaluation and magnetic resonance imaging. These measures lack sensitivity and accuracy, so new biomarkers are necessary. Several markers have been studied and to date the most promising is neurofilament light (NfL), a component of the axonal cytoskeleton, which is released into cerebrospinal fluid (CSF) following axonal damage. In the present study, we review the current knowledge about CSF NfL determination in MS, clinically isolated syndrome, and radiologically isolated syndrome, and critically discuss how CSF NfL measurement may contribute to therapeutic decision-making in these patients.Academia Brasileira de Neurologia - ABNEURO2019-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000600436Arquivos de Neuro-Psiquiatria v.77 n.6 2019reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282x20190060info:eu-repo/semantics/openAccessDOMINGUES,Renan BarrosFERNANDES,Gustavo Bruniera PeresLEITE,Fernando Brunale Vilela de MouraSENNE,Carloseng2019-07-15T00:00:00Zoai:scielo:S0004-282X2019000600436Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2019-07-15T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse |
dc.title.none.fl_str_mv |
Neurofilament light chain in the assessment of patients with multiple sclerosis |
title |
Neurofilament light chain in the assessment of patients with multiple sclerosis |
spellingShingle |
Neurofilament light chain in the assessment of patients with multiple sclerosis DOMINGUES,Renan Barros Multiple sclerosis cerebrospinal fluid neurofilament proteins demyelinating disorders enzyme-linked immunosorbent assay |
title_short |
Neurofilament light chain in the assessment of patients with multiple sclerosis |
title_full |
Neurofilament light chain in the assessment of patients with multiple sclerosis |
title_fullStr |
Neurofilament light chain in the assessment of patients with multiple sclerosis |
title_full_unstemmed |
Neurofilament light chain in the assessment of patients with multiple sclerosis |
title_sort |
Neurofilament light chain in the assessment of patients with multiple sclerosis |
author |
DOMINGUES,Renan Barros |
author_facet |
DOMINGUES,Renan Barros FERNANDES,Gustavo Bruniera Peres LEITE,Fernando Brunale Vilela de Moura SENNE,Carlos |
author_role |
author |
author2 |
FERNANDES,Gustavo Bruniera Peres LEITE,Fernando Brunale Vilela de Moura SENNE,Carlos |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
DOMINGUES,Renan Barros FERNANDES,Gustavo Bruniera Peres LEITE,Fernando Brunale Vilela de Moura SENNE,Carlos |
dc.subject.por.fl_str_mv |
Multiple sclerosis cerebrospinal fluid neurofilament proteins demyelinating disorders enzyme-linked immunosorbent assay |
topic |
Multiple sclerosis cerebrospinal fluid neurofilament proteins demyelinating disorders enzyme-linked immunosorbent assay |
description |
ABSTRACT Multiple sclerosis (MS) is an autoimmune, inflammatory, and degenerative disease of the central nervous system. Axonal degeneration is triggered by inflammation and is the pathological substrate of progressive disability in patients with MS. Therapeutic interventions can reduce inflammatory activity, thus delaying neurodegeneration and the progression of disability. Disease activity and neurodegeneration are assessed mainly through clinical evaluation and magnetic resonance imaging. These measures lack sensitivity and accuracy, so new biomarkers are necessary. Several markers have been studied and to date the most promising is neurofilament light (NfL), a component of the axonal cytoskeleton, which is released into cerebrospinal fluid (CSF) following axonal damage. In the present study, we review the current knowledge about CSF NfL determination in MS, clinically isolated syndrome, and radiologically isolated syndrome, and critically discuss how CSF NfL measurement may contribute to therapeutic decision-making in these patients. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-06-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000600436 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000600436 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/0004-282x20190060 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
dc.source.none.fl_str_mv |
Arquivos de Neuro-Psiquiatria v.77 n.6 2019 reponame:Arquivos de neuro-psiquiatria (Online) instname:Academia Brasileira de Neurologia instacron:ABNEURO |
instname_str |
Academia Brasileira de Neurologia |
instacron_str |
ABNEURO |
institution |
ABNEURO |
reponame_str |
Arquivos de neuro-psiquiatria (Online) |
collection |
Arquivos de neuro-psiquiatria (Online) |
repository.name.fl_str_mv |
Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia |
repository.mail.fl_str_mv |
||revista.arquivos@abneuro.org |
_version_ |
1754212785083908096 |